uploads///Chart

Novartis’s Alcon in Q2 2018

By

Aug. 29 2018, Updated 10:30 a.m. ET

Alcon

Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. It reported a 7% growth YoY (year-over-year) in revenues to ~$1.82 billion during Q2 2018 compared to ~$1.71 billion during the second quarter of 2017. Growth includes a 5% increase in operating revenues and a 2% favorable impact of foreign exchange.

The above chart compares the revenue trend for Alcon since the first quarter of 2017.

Article continues below advertisement

Product performance

Surgical products reported an 8% growth in operating revenues during Q2 2018, while vision care products reported a 1% growth.

US markets reported revenue growth to $750 million during Q2 2018, while the European markets reported revenue growth to $461 million. The Canada and Latin America markets reported growth in revenues to ~$159 million, and the Asia/Africa/Australasia markets reported growth in revenues to ~$449 million.

Surgical sales

Surgical sales reported a 10% growth YoY in revenues to ~$1 billion during Q2 2018 compared to $938 million during the second quarter of 2017.

Revenues from consumables increased 7% to $578 million, while revenues from implants increased 15% to $298 million. Revenues from sales of equipment and other products increased 10% to $154 million during the quarter.

Vision care

The vision care franchise reported a 3% growth YoY in revenues to ~$789 million during Q2 2018 compared to $769 million during the second quarter of 2017.

Revenues from contact lenses increased 5% to $478 million, while revenues from over-the-counter ophthalmic products decreased to $176 million. Revenues from contact lens care products decreased to $135 million.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 5.2% of its total investments in Novartis (NVS), 5.2% in Merck & Co. (MRK), 5.2% in Johnson & Johnson (JNJ), and 4.9% in AstraZeneca (AZN).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.